Join Growin Stock Community!

華上生醫7427.TW Overview

TW StockBiotech. & Medical
(No presentation for 7427)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

華上生醫（7427）Overall Performance

華上生醫（7427）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

華上生醫（7427） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

華上生醫（7427）Key Information

華上生醫（7427）Profile

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei City, Taiwan.

華上生醫（7427）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.42
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
224.11
PB Ratio
2.64
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
55.50%
Net Margin
-2251.43%
Revenue Growth (YoY)
466.75%
Profit Growth (YoY)
392.64%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.42
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
224.11
PB Ratio
2.64
Price-to-FCF
-
Gross Margin
55.50%
Net Margin
-2251.43%
Revenue Growth (YoY)
466.75%
Profit Growth (YoY)
392.64%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

7427

華上生醫

34.05D

-4.26%

(-0.04)

  • When is 7427's latest earnings report released?

    The most recent financial report for 華上生醫 (7427) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 7427's short-term business performance and financial health. For the latest updates on 7427's earnings releases, visit this page regularly.

  • How much cash does 7427 have?

    At the end of the period, 華上生醫 (7427) held Total Cash and Cash Equivalents of 187.57M, accounting for 0.32 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 7427 go with three margins increasing?

    In the latest report, 華上生醫 (7427) did not achieve the “three margins increasing” benchmark, with a gross margin of 60.51%%, operating margin of -7,042.7%%, and net margin of -7,188.92%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 7427's profit trajectory and future growth potential.